Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital SummitPRNewsWire • 12/09/21
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/12/21
Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021PRNewsWire • 11/12/21
Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021PRNewsWire • 11/12/21
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021PRNewsWire • 11/12/21
Compugen's stock jumps after Bristol Myers Squibb completes $20 million investment into the companyMarket Watch • 11/11/21
Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity InvestmentPRNewsWire • 11/11/21
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902PRNewsWire • 10/04/21
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021PRNewsWire • 10/01/21
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare ConferencePRNewsWire • 08/26/21
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical DevelopmentPRNewsWire • 08/19/21
Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207PRNewsWire • 07/19/21
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced MalignanciesPRNewsWire • 07/15/21